8-K: Fortrea Raises Revenue Guidance, Reports Mixed Q3 2025 Results

Fortrea Holdings Inc. reported third-quarter 2025 financial results, showing increased revenue and improved GAAP net loss, but a decline in adjusted EBITDA, while raising full-year revenue guidance.

Summary

• Third-quarter 2025 revenue increased to $701.3 million from $674.9 million in Q3 2024.
• GAAP net loss for Q3 2025 improved to $(15.9) million compared to $(18.5) million in Q3 2024.
• Adjusted EBITDA for Q3 2025 decreased to $50.7 million from $64.2 million in Q3 2024.
• GAAP diluted loss per share for Q3 2025 was $(0.17), an improvement from $(0.21) in Q3 2024.
• Adjusted diluted income per share for Q3 2025 decreased to $0.12 from $0.23 in Q3 2024.
• The book-to-bill ratio for the quarter was 1.13x, with a trailing 12-month ratio of 1.07x.
• Year-to-date 2025 revenue was $2,062.9 million, up from $1,999.4 million in the same period of 2024.
• Year-to-date GAAP net loss was $(953.7) million, significantly impacted by a non-cash goodwill impairment charge of $797.9 million recognized in prior quarters of 2025.
• Year-to-date adjusted net income increased to $31.2 million from $13.5 million in the same period of 2024.
• Full-year 2025 revenue guidance was raised to a range of $2,700 million to $2,750 million.
• Full-year 2025 adjusted EBITDA guidance was narrowed to a range of $175 million to $195 million.
• Net cash used for operating activities for the nine months ended September 30, 2025, was $(15.6) million, a significant decrease from $245.7 million provided in the same period of 2024.
• Free cash flow for the nine months ended September 30, 2025, was $(33.3) million.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While Q3 revenue growth and improved GAAP net loss are positive, and full-year revenue guidance was raised, the decline in Q3 adjusted EBITDA and adjusted EPS, coupled with a significant year-to-date GAAP net loss due to goodwill impairment and negative operating cash flow, temper the overall outlook. The strong book-to-bill ratio and management's confidence provide a forward-looking positive signal.

Positives

• Q3 2025 revenue increased to $701.3 million from $674.9 million in Q3 2024.
• GAAP net loss for Q3 2025 improved to $(15.9) million from $(18.5) million in Q3 2024.
• GAAP diluted loss per share for Q3 2025 improved to $(0.17) from $(0.21) in Q3 2024.
• Book-to-bill ratio of 1.13x for the quarter and 1.07x for the trailing 12 months indicates strong new business generation.
• Full-year 2025 revenue guidance was raised to a range of $2,700 million to $2,750 million.
• Year-to-date adjusted net income increased to $31.2 million from $13.5 million in the same period of 2024.
• Cost saving initiatives remain on track.
• No indicators of goodwill impairment were identified in the third quarter of 2025.

Negatives

• Adjusted EBITDA for Q3 2025 decreased to $50.7 million from $64.2 million in Q3 2024.
• Adjusted diluted income per share for Q3 2025 decreased to $0.12 from $0.23 in Q3 2024.
• Year-to-date GAAP net loss was $(953.7) million, significantly worse than $(197.6) million in 2024, primarily due to a $797.9 million non-cash goodwill impairment charge in prior quarters of 2025.
• Year-to-date adjusted EBITDA decreased to $135.9 million from $146.5 million in the same period of 2024.
• Net cash used for operating activities for the nine months ended September 30, 2025, was $(15.6) million, a substantial decline from $245.7 million provided in the same period of 2024.
• Free cash flow for the nine months ended September 30, 2025, was negative $(33.3) million.

Risks

• Inability to successfully implement business strategies and execute the long-term value creation strategy.
• Risks and expenses associated with international operations, including tariff policies, trade sanctions, other trade restrictions, and currency fluctuations.
• Customer or therapeutic area concentrations.
• Further deterioration in the macroeconomic environment or changes in government regulations and funding, potentially leading to defaults or cancellations by customers.
• Backlog and net new business may not be indicative of future revenues, and the company might not realize all anticipated future revenue reflected in backlog.
• Inability to generate sufficient net new business awards, or delays, terminations, or reductions in scope of such awards.
• Costs or impacts on internal controls related to the establishment and improvement of accounting and other management systems.
• Underpricing contracts, overrunning cost estimates, or failing to receive approval for, or experiencing delays in documentation of change orders.

Future Outlook

Fortrea is raising its full-year 2025 revenue guidance to a range of $2,700 million to $2,750 million, indicating an expectation of continued top-line growth. The company is also narrowing its adjusted EBITDA guidance to a range of $175 million to $195 million, reflecting a more precise outlook on profitability. Management expressed confidence in the company's global footprint, capabilities, expertise, technology, and innovation to achieve its goals, emphasizing a commitment to operational, commercial, and financial excellence.

Management Comments

• "Fortrea delivered a solid performance that met expectations in the third quarter by partnering with our clients and advancing the development of potentially life-changing treatments for patients."
• "Pleased with how our strong team moved quickly through our leadership transition without missing a beat."
• "Confident that we have the global footprint, differentiated capabilities, therapeutic expertise, technology and innovation needed to deliver on our goals."
• "Committed to executing our plans with operational, commercial and financial excellence."

Industry Context

Fortrea operates as a leading global contract research organization (CRO), a sector critical to the life sciences industry for accelerating drug development. The reported results, particularly the strong book-to-bill ratio and increased revenue guidance, suggest a healthy demand for clinical development services. The industry continues to benefit from ongoing R&D investments by biopharmaceutical, biotechnology, medical device, and diagnostic companies, despite macroeconomic headwinds that contributed to Fortrea's goodwill impairment earlier in the year. Fortrea's focus on operational excellence and leveraging its global footprint aligns with broader industry trends towards efficiency and specialized expertise in complex clinical trials.

Stakeholder Impact

• Shareholders: Potential positive impact from raised revenue guidance and strong book-to-bill, but tempered by declining adjusted EBITDA and significant YTD GAAP net loss due to impairment. The negative free cash flow could be a concern.
• Employees: Management's commitment to operational excellence and cost-saving initiatives could imply efficiency drives, but no direct impact on employment levels is stated. The CEO's positive comments about the team suggest stability.
• Customers: Strong book-to-bill ratio and management's focus on client partnerships indicate continued engagement and value delivery.
• Creditors: Long-term debt remains stable, but negative operating cash flow and free cash flow could be a point of monitoring.

Next Steps

• Host a conference call on November 5, 2025, at 8:00 am ET to review Q3 financial results and conduct a Q&A session.
• Continue executing plans with operational, commercial, and financial excellence.
• Update or revise forward-looking statements as required by law.

Key Dates

Recommendation

Fortrea presents a mixed financial picture. The increase in Q3 revenue, improved GAAP net loss, and a strong book-to-bill ratio, coupled with raised full-year revenue guidance, are positive indicators of business momentum and demand for its CRO services. Management's confidence in the company's capabilities and strategic execution is also encouraging. However, the decline in Q3 adjusted EBITDA and adjusted EPS, along with a substantial year-to-date GAAP net loss driven by a significant goodwill impairment charge, and negative operating cash flow, highlight profitability and cash generation challenges. The narrowing of adjusted EBITDA guidance suggests a more cautious outlook on near-term profitability. Given these offsetting factors, a "hold" recommendation is appropriate as investors should monitor the company's ability to translate its strong backlog into improved adjusted profitability and positive cash flow in future quarters, especially after the impact of the goodwill impairment.

Keywords

Fortrea Holdings Inc., FTRE, Contract Research Organization, CRO, Clinical Development, Financial Results, Q3 2025, Earnings, Revenue Guidance, Adjusted EBITDA, Goodwill Impairment, Book-to-bill, Life Sciences, Biopharmaceutical, Biotechnology, Clinical Trials